John R Hawse1, Jodi M Carter2, Kirsten G M Aspros3, Elizabeth S Bruinsma3, Justin W Koepplin2, Vivian Negron4, Malayannan Subramaniam3, James N Ingle5, Karen L Rech2, Matthew P Goetz5,6. 1. Department of Biochemistry and Molecular Biology, Mayo Clinic, 13-21B Guggenheim Building, 200 First St. SW, Rochester, MN, 55905, USA. hawse.john@mayo.edu. 2. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. 3. Department of Biochemistry and Molecular Biology, Mayo Clinic, 13-21B Guggenheim Building, 200 First St. SW, Rochester, MN, 55905, USA. 4. Department of Pathology, Mayo Clinic, Rochester, MN, USA. 5. Department of Oncology, Mayo Clinic, Rochester, MN, USA. 6. Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.
Abstract
PURPOSE: Significant controversy exists regarding the expression patterns of estrogen receptor beta (ERβ) in normal and diseased breast tissue. To address this issue, we have validated two ERβ antibodies, optimized the IHC protocols for both antibodies and now report the expression patterns of ERβ in normal and malignant breast tissues. METHODS: ERβ antibody specificity was determined using western blot and IHC analysis. ERβ protein expression patterns were assessed via IHC in normal breast tissue and invasive breast carcinoma. Further, we report the detailed protocol of the ERβ IHC assay developed in our CAP/CLIA certified laboratory to provide a standardized method for future studies. RESULTS: We have confirmed the specificity of two independent ERβ monoclonal antibodies, one that detects total (i.e., full length plus splice variants 2-5, which do not include the ligand binding domain) ERβ protein (PPZ0506) and one that detects only the full-length form, which includes the ligand binding domain, of ERβ (PPG5/10). Using these two antibodies, we demonstrate that ERβ is highly expressed in normal human breast tissue as well as in 20-30% of invasive breast cancers. Further, these two antibodies exhibited similar staining patterns across multiple different tissues and were highly concordant with regard to determining ERβ positivity in breast cancers. CONCLUSIONS: ERβ protein was shown to be abundant in the majority of normal breast epithelial cells and is present in 20-30% of breast cancers. Use of these two antibodies, along with their standardized IHC protocols, provide a reference for future studies aimed at determining the utility of ERβ as a prognostic and/or predictive biomarker in various tissues of benign or malignant states.
PURPOSE: Significant controversy exists regarding the expression patterns of estrogen receptor beta (ERβ) in normal and diseased breast tissue. To address this issue, we have validated two ERβ antibodies, optimized the IHC protocols for both antibodies and now report the expression patterns of ERβ in normal and malignant breast tissues. METHODS: ERβ antibody specificity was determined using western blot and IHC analysis. ERβ protein expression patterns were assessed via IHC in normal breast tissue and invasive breast carcinoma. Further, we report the detailed protocol of the ERβ IHC assay developed in our CAP/CLIA certified laboratory to provide a standardized method for future studies. RESULTS: We have confirmed the specificity of two independent ERβ monoclonal antibodies, one that detects total (i.e., full length plus splice variants 2-5, which do not include the ligand binding domain) ERβ protein (PPZ0506) and one that detects only the full-length form, which includes the ligand binding domain, of ERβ (PPG5/10). Using these two antibodies, we demonstrate that ERβ is highly expressed in normal human breast tissue as well as in 20-30% of invasive breast cancers. Further, these two antibodies exhibited similar staining patterns across multiple different tissues and were highly concordant with regard to determining ERβ positivity in breast cancers. CONCLUSIONS: ERβ protein was shown to be abundant in the majority of normal breast epithelial cells and is present in 20-30% of breast cancers. Use of these two antibodies, along with their standardized IHC protocols, provide a reference for future studies aimed at determining the utility of ERβ as a prognostic and/or predictive biomarker in various tissues of benign or malignant states.
Entities:
Keywords:
Antibody; Breast; Breast cancer; Estrogen receptor beta
Authors: Jin Wang; Chao Zhang; Keming Chen; Hailin Tang; Jun Tang; Cailu Song; Xiaoming Xie Journal: Breast Cancer Res Treat Date: 2015-06-13 Impact factor: 4.872
Authors: David G Monroe; Barbara J Getz; Steven A Johnsen; B Lawrence Riggs; Sundeep Khosla; Thomas C Spelsberg Journal: J Cell Biochem Date: 2003-10-01 Impact factor: 4.429
Authors: Suzanne A W Fuqua; Rachel Schiff; Irma Parra; John T Moore; Syed K Mohsin; C Kent Osborne; Gary M Clark; D Craig Allred Journal: Cancer Res Date: 2003-05-15 Impact factor: 12.701
Authors: Fergal J Fleming; Arnold D K Hill; Enda W McDermott; Niall J O'Higgins; Leonie S Young Journal: J Clin Endocrinol Metab Date: 2004-01 Impact factor: 5.958
Authors: Jordan M Reese; Elizabeth S Bruinsma; David G Monroe; Vivian Negron; Vera J Suman; James N Ingle; Matthew P Goetz; John R Hawse Journal: Oncotarget Date: 2017-10-11
Authors: Shunchao Yan; Parama Dey; Yvonne Ziegler; Xin Jiao; Sung Hoon Kim; John A Katzenellenbogen; Benita S Katzenellenbogen Journal: Breast Cancer Res Treat Date: 2020-10-01 Impact factor: 4.872